Press Release: Novartis receives positive CHMP -2-

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177--PSMA-617 for

Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi:

10.1056/NEJMoa2107322.

2. World Health Organization (WHO). (2022) Cancer population fact sheet:

Europe. Retrieved

from https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fac

t-sheets.pdf

3. SEER. Cancer stat facts: prostate cancer April 2021.

[https://seer.cancer.gov/statfacts/html/prost.html]

4. Hope TA, Aggarwal R, Chee B, et al. Impact of 68Ga-PSMA-11 PET on

management in patients with biochemically recurrent prostate cancer. J

Nucl Med 2017;58(12):1956--61

5. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific

membrane antigen (PSMA) on biopsies is an independent risk stratifier of

prostate cancer patients at time of initial diagnosis. Front Oncol

2018;8:623.

6. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane

antigen expression in prostatic intraepithelial neoplasia and

adenocarcinoma: a study of 184 cases. Cancer 1998;82(11):2256--61

7. Pomykala KL, Czernin J, Grogan TR, et al. Total-body 68Ga-PSMA-11 PET/CT

for bone metastasis detection in prostate cancer patients: potential

impact on bone scan guidelines. J Nucl Med 2020;61(3):405--11

8. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is

associated with early PSA recurrence in surgically treated prostate

cancer. Prostate 2011;71(3):281--8

9. Hofman MS, Violet J, Hicks RJ et al. [177Lu]-PSMA-617 radionuclide

treatment in patients with metastatic castration-resistant prostate

cancer (LuPSMA trial): a single-centre, single-arm, phase 2.

10. Sant GR, Knopf KB, Albala DM. Live-single-cell phenotypic cancer

biomarkers-future role in precision oncology? NPJ Precision Oncology

2017;1(1):21

11. Novartis Pharmaceuticals. 177Lu-PSMA-617 vs. Androgen Receptor-directed

Therapy in the Treatment of Progressive Metastatic Castrate Resistant

Prostate Cancer (PSMAfore). U.S. National Library of Medicine: Clinical

Trials. 2020; NCT04689828.

12. Novartis Pharmaceuticals. An International Prospective Open-label,

Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With

Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition).

U.S. National Library of Medicine: Clinical Trials. 2021; NCT04720157.

13. Sung H, Ferlay J, Siegel RL, Sung H, et al. Global cancer statistics

2020: GLOBOCAN estimates of incidence and mortality worldwide for 36

cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

doi:10.3322/caac.21660.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Fran Rodrigues

Novartis External Communications Novartis Innovative Medicines

+41 79 392 8697 (mobile) International Communications

anja.von_treskow@novartis.com +41 79 413 4942

Julie Masow fran.rodrigues@novartis.com

Novartis US External Communications

+1 862 579 8456 (mobile)

julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

October 14, 2022 07:04 ET (11:04 GMT)